In the latest quarter, 6 analysts provided ratings for Enovis (NYSE:ENOV), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $78.67, with a high estimate of $82.00 and a low estimate of $72.00. Surpassing the previous average price target of $73.00, the current average has increased by 7.77%.
Breaking Down Analyst Ratings: A Detailed Examination
A comprehensive examination of how financial experts perceive Enovis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Maintains | Buy | $82.00 | - |
| Mike Matson | Needham | Maintains | Buy | $82.00 | - |
| Vik Chopra | Wells Fargo | Raises | Overweight | $79.00 | $73.00 |
| Caitlin Cronin | Canaccord Genuity | Raises | Buy | $75.00 | $73.00 |
| Mike Matson | Needham | Raises | Buy | $82.00 | $73.00 |
| George Sellers | Stephens & Co. | Announces | Overweight | $72.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Enovis. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Enovis compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Enovis's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Enovis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Enovis analyst ratings.
Get to Know Enovis Better
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.
Enovis: A Financial Overview
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Enovis's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 11.33%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Enovis's net margin is impressive, surpassing industry averages. With a net margin of 0.65%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Enovis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.09% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Enovis's ROA excels beyond industry benchmarks, reaching 0.07%. This signifies efficient management of assets and strong financial health.
Debt Management: Enovis's debt-to-equity ratio is below the industry average. With a ratio of 0.16, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.